Actively Recruiting
Interest of Sublingual Videomicroscopy for the Prediction of Bleeding in Von Willebrand Disease and Other Constitutional Haemorrhagic Diseases
Led by University Hospital, Lille · Updated on 2026-05-20
400
Participants Needed
1
Research Sites
N/A
Total Duration
On this page
AI-Summary
What this Trial Is About
Researchers are investigating whether sublingual videomicroscopy, a non-invasive and sensitive technique that analyzes capillary density under the tongue, can predict bleeding risk in patients with von Willebrand disease and other congenital bleeding disorders such as Glanzmann Thrombasthenia and moderate to severe Hemophilia A, including women carrying the hemophilia gene. This study addresses the current lack of non-invasive tests to identify patients at high risk of bleeding from angiodysplasias. Participants will undergo sublingual videomicroscopy to measure capillary density, alongside blood sample collection at the start and after 36 months. The study includes two groups: patients with hemorrhagic diseases and a control group. The primary focus is to assess the predictive value of sublingual capillary density for significant bleeding events over three years. During the study, participants will have baseline and three-year evaluations including capillary density, qualitative capillary abnormalities, bleeding scores using the ISTH-BAT tool, and plasma levels of proangiogenic markers such as galectine and VEGF. The main outcome is the correlation between capillary density and bleeding events within three years. The study spans three years, monitoring participants’ bleeding risk and related biological markers over this period.
CONDITIONS
Brief Title
Videomicroscopy for the Prediction of Bleeding in Constitutional Haemorrhagic Diseases
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Adult patient with a significant form of von Willebrand disease, Glanzmann Thrombasthenia, moderate to severe Haemophilia A, or a woman carrying the hemophilia gene
- Social insured patient
You will not qualify if you...
- Minor patient
- Refusal of consent
- Person benefiting from a system of legal protection
- Pregnant patient
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - At baseline and over 3 years
Participants undergo sublingual videomicroscopy to measure capillary density and blood samples are collected to assess biomarkers related to bleeding disorders.
2 visits (baseline and at 3 years)
Duration - 3 years
Participants are monitored for clinically significant hemorrhagic events and changes in bleeding assessment scores and biomarkers during the 3-year study period.
Follow-up visits at baseline and at 3 years
Trial Site Locations
Total: 1 location
1
CHU de Lille
Lille, Nord, France, 59000
Actively Recruiting
Research Team
A
Antoine Rauch, MD,PhD
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
PARALLEL
Primary Purpose
DIAGNOSTIC
Number of Arms
2
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here